I. M. Mcdonald

发表

2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.

J. G. Vinter, C. Low, M. Tozer, 2000, Journal of medicinal chemistry.

Novel oxathiazinones as gastrin ligands : Unexpected preducts from the schotten-baumann reaction of arylsulphonyl chlorides with derivatives of aspartic acid

C. Low, H. Broughton, I. M. Mcdonald, 1992 .

2-NAP: a selective, hydrophilic, non-peptide CCKA - receptor antagonist derived from the cholecystokinin C-terminal dipeptide.

M. Bodkin, C. Low, H. Broughton, 1993 .

Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.

C. Low, C. Austin, I. Buck, 2006, Journal of medicinal chemistry.

Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.

J. Black, C. Low, N. Shankley, 2005, Journal of medicinal chemistry.

Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.

J. Black, C. Low, H. Broughton, 2000, Journal of medicinal chemistry.

Improving the Affinity and Selectivity of a Nonpeptide Series of Cholecystokinin‐B/Gastrin Receptor Antagonists Based on the Dibenzobicyclo(2.2.2)octane Skeleton.

C. Low, M. Hudson, M. Tozer, 1996 .

A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.

M. Bodkin, C. Low, I. Buck, 1994, Journal of medicinal chemistry.

Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.

J. G. Vinter, C. Low, M. Hudson, 1996, Journal of medicinal chemistry.

Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.

Eric Griffin, I. M. Mcdonald, I. Linney, 2008, Bioorganic & medicinal chemistry.

CCK2 receptor antagonists

I. M. Mcdonald, Iain M McDonald, 2001 .

Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.

C. Low, C. Austin, D. Sykes, 2007, Journal of medicinal chemistry.

Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.

J. Black, D. Sykes, I. Buck, 2007, Journal of medicinal chemistry.

4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: the design of potent histamine H3 receptor antagonists.

M. Tozer, I. Buck, I. M. Mcdonald, 1999, Bioorganic & medicinal chemistry letters.

An unusual oxidative rearrangement of azabicyclo[2.2.1]heptenes, providing a stereoselective route to 2′- and 3′-hydroxycyclopentylglycines

G. Rosair, P. Bailey, I. M. Mcdonald, 2000 .

An Unusual Oxidative Rearrangement of Azabicyclo[2.2.1]heptenes, Providing a Stereoselective Route to 2′- and 3′-Hydroxycyclopentylglycines.

G. Rosair, P. Bailey, I. M. Mcdonald, 2001 .

Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand.

I. M. Mcdonald, S. Kalindjian, 2007, Current Topics in Medicinal Chemistry.

Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton.

C. Low, M. Hudson, M. Tozer, 1995, Journal of medicinal chemistry.